S-1/A: Kyverna Therapeutics Eyes Public Markets with $182.3 Million IPO to Advance Autoimmune Cell Therapies

Kyverna Therapeutics is seeking to raise approximately $182.3 million through an initial public offering to further the clinical development of its cell therapies for autoimmune diseases.

Summary

• Kyverna Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1/A form to register for an initial public offering (IPO).
• The company plans to offer 11,120,000 shares of its common stock to the public.
• The estimated initial public offering price is between $17.00 and $19.00 per share.
• Kyverna has applied to list its common stock on the Nasdaq Global Market under the ticker symbol KYTX.
• The company estimates net proceeds from the IPO to be approximately $182.3 million, or $210.2 million if underwriters exercise their option.
• The primary use of proceeds will be to advance clinical development of KYV-101, advance KYV-201 into clinical development, fund research and development, and for general corporate purposes.
• Kyverna is focused on developing cell therapies for autoimmune diseases, with lead product candidate KYV-101 targeting lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis.
• The company has partnered with Intellia Therapeutics to develop KYV-201, an allogeneic CD19 CAR T-cell product candidate.
• Kyverna has incurred net losses since inception, with a net loss of $39.7 million for the nine months ended September 30, 2023, and expects to continue incurring significant losses.
• The company's management and independent registered public accounting firm have concluded that there is substantial doubt as to the company's ability to continue as a going concern.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has promising technology and clinical programs, it also faces significant financial challenges and risks. The sentiment is neutral, reflecting both the potential and the uncertainties.

Positives

• Kyverna has a clear clinical development path for KYV-101 across rheumatology and neurology.
• The company's cell therapy approach is supported by scientific publications and early clinical data.
• KYV-101 has shown improved tolerability in a Phase 1 oncology trial compared to Yescarta.
• The company is actively developing an allogeneic approach (KYV-201) to broaden patient access.
• Kyverna has partnerships with Intellia Therapeutics and WuXi ATU Advanced Therapies.
• The company has received IND clearance for KYV-101 in systemic sclerosis, myasthenia gravis, and multiple sclerosis.

Negatives

• Kyverna has a limited operating history and has incurred substantial net losses since inception.
• The company has no products approved for commercial sale and has not generated any revenue from product sales.
• The company's management and independent registered public accounting firm have concluded that there is substantial doubt as to the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The FDA is investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies, such as KYV-101.

Risks

• The company's business depends entirely on the success of its product candidates, and there is no guarantee of successful completion of development, regulatory approval, or commercialization.
• Preclinical and clinical development is a lengthy and expensive process with an uncertain outcome.
• Results of earlier studies and trials may not be predictive of future trial results.
• The company faces competition from entities with greater resources and experience.
• Use of the company's product candidates could be associated with side effects, adverse events, or other safety risks.
• The company relies on third-party manufacturers and suppliers, and their failure to comply with requirements or supply sufficient quantities would materially affect the business.
• The company depends on intellectual property licensed from third parties, and termination of these licenses could result in the loss of significant rights.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable.
• An active and liquid trading market for the company's common stock may not develop.
• The company's principal stockholders and management own a significant percentage of the common stock and will be able to control matters subject to stockholder approval.
• Unfavorable global economic conditions could adversely affect the company's business, financial condition, results of operations, or liquidity.

Future Outlook

Kyverna expects to continue to incur substantial losses for the foreseeable future and will need to raise additional capital to fund its operations.

Industry Context

The document highlights the increasing prevalence of autoimmune diseases and the limitations of current treatments, positioning cell therapies as a potential solution. It also acknowledges the competitive landscape and the need to demonstrate superior efficacy and safety compared to existing therapies.

Comparison to Industry Standards

• The document compares KYV-101's underlying CAR (Hu19-CD828Z) to the CAR used in Yescarta (FMC63-28Z), noting lower levels of inflammatory cytokines and neurotoxicity in the NIH Phase 1 trial.
• The document references the ZUMA-7 trial of Yescarta to compare antitumor responses with Hu19-CD828Z CAR T cells.
• The document references clinical data published in Nature Medicine in September 2022, a CD19 CAR T-cell therapy was observed to induce clinical remission in all five systemic lupus erythematosus patients with lupus nephritis.
• The document references clinical data published in the New England Journal of Medicine in 2021, a 20-year-old woman with severe and refractory SLE was observed to experience rapid remission of symptoms and autoantibody levels following a single treatment with autologous CD19 CAR T cells.

Related Party Transactions

• The document mentions related party transactions, including collaboration revenue from Gilead Sciences and the issuance of Series B preferred stock to Intellia Therapeutics.
• The document mentions that jVen Capital, LLC is an entity controlled by an immediate family member of Mr. Ryan Jones, our Chief Financial Officer.

Stakeholder Impact

• Shareholders: Potential for increased value if the company successfully develops and commercializes its product candidates, but also risk of dilution and loss of investment.
• Employees: Opportunity to work on innovative therapies and benefit from equity compensation, but also risk of job loss if the company is unsuccessful.
• Patients: Potential for new and effective treatments for autoimmune diseases, but also risk of side effects and lack of access.
• Creditors: Risk of non-payment if the company is unable to raise additional capital or generate revenue.

Next Steps

• Advance clinical development of KYV-101 in rheumatology and neurology.
• Advance KYV-201 through preclinical development and into clinical trials.
• Expand access and clinical experience with product candidates through investigator-initiated trials and named patient activities.
• Invest in early-stage research programs to expand the pipeline and capabilities.
• Invest in technologies to prepare for commercialization and evaluate strategic partnerships.

Key Dates

Keywords

Kyverna Therapeutics, IPO, KYV-101, KYV-201, autoimmune diseases, cell therapy, clinical trials, FDA, B cells, CAR T-cell, lupus nephritis, systemic sclerosis, myasthenia gravis, multiple sclerosis, Intellia Therapeutics, WuXi ATU, ElevateBio, NIH, CD19